Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years

Abstract Introduction Upadacitinib (UPA) is a Janus kinase inhibitor that has demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA) with an acceptable safety profile. We investigated laboratory parameter changes in UPA RA clinical trials. Methods Pooled data from six randomized trial...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Christina Charles-Schoeman, Jon T. Giles, Nancy E. Lane, Ernest Choy, Daniel E. Furst, Jiří Vencovský, Anthony G. Wilson, Gerd R. Burmester, Derek Coombs, Sara K. Penn, Nasser Khan, Jillian B. Yee, Kassim Rahawi, Iain B. McInnes
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Adis, Springer Healthcare 2024-01-01
סדרה:	Rheumatology and Therapy
נושאים:	JAK inhibitor Laboratory parameters Rheumatoid arthritis Upadacitinib
גישה מקוונת:	https://doi.org/10.1007/s40744-023-00624-3
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!